Anti-C1s Humanized IgG4 Monoclonal Antibody (Bioverativ)

N/A

Report date: 2025/06/11 11:18:48

Base Information

Drug NameAnti-C1s Humanized IgG4 Monoclonal Antibody (Bioverativ)
Drug Alias NameAnti-C1s Humanized IgG4 Monoclonal Antibody (Biover)complement system-targeting monoclonal antibodies (Bioverativ)TNT-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C1s inhibitorsImmunomodulators
TargetsComplement C1s
Therapy Area/IndicationsImmune System DiseasesNeuromuscular DiseasesMotor Neuron Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBioverativ Inc
China Registration ClassN/A

Develop Information

Active CompaniesBioverativ Inc
Inactive CompaniesN/A
Active IndicationsNeuromuscular DiseasesMotor Neuron DiseasePolyradiculoneuropathy, Chronic Inflammatory Demyelinating +[4] 
Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A
Related LinksN/A